Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020.
Ontario
amphetamines
emergency department
marginalization
Journal
Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
medline:
23
10
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
Despite unregulated amphetamine use increasing, there are limited data on related emergency department (ED) visits in Canada. Our primary objective was to examine trends in amphetamine-related ED visits over time in Ontario, including by age and sex. Secondary objectives were to examine whether patient characteristics were associated with ED revisit within 6 months. Using administrative claims and census data, we calculated annual patient- and encounter-based rates of amphetamine-related ED visits from 2003 to 2020 among individuals 18+ years of age. We also performed a retrospective cohort study of individuals with amphetamine-related ED visits between 2019 and 2020 to determine whether select factors were associated with ED revisit within 6 months. Multivariable logistic regression modelling was used to measure associations. The population-based rate of amphetamine-related ED visits increased nearly 15-fold between 2003 (1.9/100,000 Ontarians) and 2020 (27.9/100,000 Ontarians). Seventy-five percent of individuals returned to the ED for any reason within 6 months. Psychosis and use of other substances were both independently associated with ED revisit for any reason within 6 months (psychosis: AOR = 1.54, 95% CI = 1.30-1.83; other substances: AOR = 1.84, 95% CI = 1.57-2.15), whereas having a primary care physician was negatively associated with ED revisit (AOR = 0.77, 95% CI = 0.60-0.98). Increasing rates of amphetamine-related ED visits in Ontario are cause for concern. Diagnoses of psychosis and the use of other substances may serve to identify individuals who are most likely to benefit from both primary and substance-specific care.
Identifiants
pubmed: 36891572
doi: 10.1177/07067437231158933
pmc: PMC10590093
doi:
Substances chimiques
Amphetamine
CK833KGX7E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-849Subventions
Organisme : CIHR
ID : 201909MPU
Pays : Canada
Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Can Fam Physician. 2019 May;65(5):343-351
pubmed: 31088874
Acad Emerg Med. 2019 Dec;26(12):1336-1345
pubmed: 31162887
JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342
pubmed: 34550301
Addict Behav. 2004 Jan;29(1):89-106
pubmed: 14667423
Harm Reduct J. 2017 Jun 5;14(1):31
pubmed: 28583136
Drug Alcohol Depend. 2018 Dec 1;193:14-20
pubmed: 30326396
Drug Alcohol Rev. 2020 Nov;39(7):932-940
pubmed: 32666650
J Addict. 2017;2017:4050932
pubmed: 28913001
PLoS One. 2021 May 26;16(5):e0252090
pubmed: 34038452
BMJ Open. 2022 May 2;12(5):e060447
pubmed: 35501101
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
Epidemiol Rev. 2020 Jan 31;42(1):154-166
pubmed: 33511987
J Drug Issues. 2010 Dec;40(1):7-26
pubmed: 21052519
JAMA Netw Open. 2021 Apr 1;4(4):e215902
pubmed: 33852001
PLoS Med. 2021 Jun 1;18(6):e1003631
pubmed: 34061846
Drug Alcohol Rev. 2020 Jul;39(5):505-518
pubmed: 32212214
JAMA Netw Open. 2018 Oct 5;1(6):e183758
pubmed: 30646256